Near Infrared Analysis of Tablets Containing Two Active Ingredients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Near Infrared Analysis of Tablets Containing Two Active Ingredients
The study evaluates near-infrared analysis of tablets nominally containing 4 mg of chlorpheniramine maleate and 10 mg of phenylephrine hydrochloride per dose.


Pharmaceutical Technology
pp. 52-62


Table III: Phenylephrine (PE)–HCl repeatability.
The Vision software has a routine-analysis method for calculating CU automatically and produces a report that complies with 21 CFR Part 11. Table IV shows the CU results for 4.0 mg CPM in T-5 label claim tablets. Data out of the 15% of label-claim range because of processing difficulties are in red. Table V shows the CU results for 10.0 mg PE–HCl in the same tablets.


Table IV: Content uniformity of chlorpheniramine maleate. Relative standard deviation = 4.573%.
Table VI shows the HPLC data in percent of label claim for the nominal label claim of batch T-5. The mean value for CPM (target label claim of 4.0 mg) was extremely low because of formulation and tablet-processing problems. While the variance (i.e., RSD) was not more than 6.0 % in the T-5 values, T-3 for PE–HCL was 6.26%, and T-9 for CPM was 6.68% (see Table VI).

Conclusion


Table V: Content uniformity of phenylephrine–HCl. Relative standard deviation = 1.627%.
This study shows that the NIR assay for the determination of tablets' CU is a fast and accurate means of monitoring tablets that could be used for production and is consistent with FDA's PAT initiative. The data showed promising results that could relieve laboratory workload and bring analysis closer to real time for process monitoring. Ten tablets could be analyzed in less than 3 min. The results would be improved by eliminating processing problems that led to high within-batch variance (i.e., as high as 11.95% RSD in N-1 CPM) and meeting target label-claim values.


Table VI: High-performance liquid chromatography data for percent of nominal label claims and batch levels tablets. Data out of the 15% of label claim range and relative standard deviations above 6.0% are in red.
Robert Mattes* is an applications scientist, and Denise Root is the marketing and product specialist manager, both at FOSS NIRSystems, 7703 Montpelier Rd., Laurel, MD 20723, tel. 301.680.7251, fax 301.236.0134,
. Ed Brunson is an instructor of pharmaceutical sciences, Suresh Potharaju is a graduate student, Wen Qu is a research associate, James Johnson is an associate professor of pharmaceutics, and Hassan Almoazen is an assistant professor of pharmaceutics, all at the University of Tennessee Health Science Center.

*To whom all correspondence should be addressed.

Submitted: July 18, 2011. Accepted: Sept. 26, 2011.

References

1. J. Workman, Jr., Handbook of Near-Infrared Analysis, D.A. Burns and E.W. Ciuczak, Eds. (Marcel Dekker, New York, 2nd ed., 2001), p. 94.

2. K.R. Beebe, R.J. Pell, and M.B. Seasholtz, Chemometrics: A Practical Guide, (John Wiley and Sons, Hoboken, NJ, 1998), p. 1.

3. FDA, PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (Rockville, MD, Sept. 2004).

4. R. Mattes et al., Pharm. Technol. 31 (4), 170–182 (2007).

5. P.J. Larkin, E. Fruhling, and C. Longfellow, Am. Pharm. Rev. 9 (6) (2006).

6. R. Kramer, Chemometric Techniques for Quantitative Analysis, (Marcel Dekker, New York, 1998), p. 60.

7. J. Workman, Jr. and L. Weyer, Practical Guide to Interpretive Near-Infrared Spectroscopy, (CRC Press, Boca Raton, FL, 2008), p. 43.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here